ABSTRACT
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the highligh of lipid-lowering therapy due to its effect on LDL-C in the cardiovascular field. PCSK9 inhibitor has become the hot spot in biological preparations in these years, but the properties of adverse reaction, high price and injection-methods of biologicals limit its development. Currently, it was reported that many traditional Chinese medicine and natural products had the functions of regulating PCSK9. This paper summarized the regulation and mechanisms of traditional Chinese medicine monomers, active ingredients, compounds and natural products on PCSK9 so as to provide references for the development of small-molecule inhibitors of PCSK9.
ABSTRACT
OBJECTIVE:To investigate the effects of MTP gene polymorphism on the lipid-regulating effect of simvastatin in the treatment of T2DM complicating with lipid metabolism disorder. METHODS:120 T2DM inpatients with hypercholesterolemia were selected from our hospital during Jun. to Dec. 2015 and given Metformin hydrochloride sustained-release tablets,Enalapril ma-leate tablets and Simvastatin tablets. PCR-RFLP was used to detect MTP G493T genotype. The levels of TG,TC,LDL-C and HDL-C were detected by AU 400 automatic biochemistry analyzer before treatment and the 4th week after treatment. The effects of different genotype on the change of blood lipid level was analyzed. RESULTS:Among 120 patients,the patients with MTP G493T GG,GT,TT genotypes accounted for 61.67%,26.67% and 11.67%,respectively,meeting Hardy-Weinberg balance(P>0.05). Before treatment,there was no statistical significance in TC,TG,LDL-C and HDL-C among different genotypes(P>0.05). After 4 weeks of treatment,the decrease of TC and LDL-C in TT genotype patients were lower than that in GG and GT genotype,with statistical significance(P>0.05). There was no significant difference in the decrease of TC and LDL-C between GT and GG geno-type,the decrease of TG and HDL-C(P>0.05). There was no significant difference in the incidence of ADR among different geno-types(P>0.05). CONCLUSIONS:After simvastatin treatment,the improvement of TC and LDL-C in patients with TT genotype is poor. MTP G493T gene polymorphism may be associated with the lipid-regulating effect of simvastatin in the treatment of T2DM patients with lipid metabolism disorder.
ABSTRACT
Niacin, a broad-spectrum lipid-regulating agent, can significantly lower plasma triglyceride and raise the high density lipoprotein-cholesterol.Extended-release niacin added to statins monotherapy could further modify the lipid profile and reduce residual cardiovascular risk.This combination therapy provides a safe, effective and economical treatment for clinicians and may be superior to other drugs combined with statins.
ABSTRACT
Recent reports have indicated that Statins could remarkably improve the prognosis of patients suffered from coronary artery disease.And this effect is not only due to Statin's lipid-regulating function,but also correlated to its non-lipid-regulating action.Atorvastatin is the latest kind of statins.In this article,we specified the non-lipid-regulating effect of Atorvastatin in the prevention and therapy to coronary artery disease.Furthermore,we summarized its corresponding clinical evaluation or security.